Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: Results from a multicentric european prospective study

European Urology

Volumn 68, Issue 1, 2015, Pages 132-138

  Fossati, Nicola ^a   Buffi, Nicolò Maria ^a   Haese, Alexander ^b   Stephan, Carsten ^c   Larcher, Alessandro ^a   McNicholas, Thomas ^d   De La Taille, Alexandre ^e   Freschi, Massimo ^f   Lughezzani, Giovanni ^a   Abrate, Alberto ^a   Bini, Vittorio ^g   Redorta, Joan Palou ^h   Graefen, Markus ^b   Guazzoni, Giorgio ^a   Lazzeri, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LISTER HOSPITAL   (United Kingdom)

^e Mondor Hospital   (France)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h FUNDACIÓ PUIGVERT   (Spain)

Author keywords

Biomarkers; p2PSA; Pathologic outcomes; Predictive models; Prostate cancer; Prostate Health Index

Indexed keywords

FREE PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN ISOFORM P2PSA; TOTAL PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; (-2)PRO-PROSTATE-SPECIFIC ANTIGEN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER SURGERY; CLINICAL DECISION MAKING; COHORT ANALYSIS; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATECTOMY; ROBOT ASSISTED SURGERY; TUMOR BIOPSY; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; LYMPH NODE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; PROSTATIC NEOPLASMS; STATISTICAL MODEL;

AGED; BIOMARKERS, TUMOR; COHORT STUDIES; HUMANS; KALLIKREINS; LOGISTIC MODELS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS;

EID: 84942984980     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.07.034     Document Type: Article

References (23)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
2. CenterMM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61: 1079-92.
3. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Gö teborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
4. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1-10.
5. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013;63:986-94.
6. Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66.
7. Anscombe FJ. Topics in the investigation of linear relations fitted by the method of least squares (with discussion). J Royal Stat Soc B 1967;29:1-52.
8. Lughezzani G, Lazzeri M, Haese A, et al. Multicenter European external validation of a Prostate Health Index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol 2014; 66:906-12.
9. Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C. Pre-Analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010;43:926-8.
10. van der Kwast TH, Amin MB, Billis A, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011;24: 16-25.
11. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
12. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-74.
13. Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010;58:687-700.
14. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
15. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010;8:145.
16. Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185:869-75.
17. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171:2339-44.
18. Sokoll LJ, SandaMG, Feng Z, et al. A prospective,multicenter,National Cancer Institute Early Detection Research Network Study of [-2]proPSA: improving prostate cancerdetectionand correlatingwith cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19: 1193-200.
19. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650-5.
20. Jansen FH, van Schaik RHN, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
21. Makarov DV, Isharwal S, Sokoll LJ, et al. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009;15:7316-21.
22. Isharwal S, Makarov DV, Sokoll LJ, et al. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011;77, 763.e1-6.
23. Tosoian JJ, Loeb S, Feng Z, et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012;188:1131-6.